ReviewCurrent oncology reports2017
Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.
Review in Current oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts.Blood advances · 2025Review
- Minimal Residual Disease in the Management of B-Cell Acute Lymphoblastic Leukemia: A Systematic Review of Studies from Indian Settings.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024Review
- How to Manage Philadelphia-Positive Acute Lymphoblastic Leukemia in Resource-Constrained Settings.Cancers · 2023Review
- Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies.Cancers · 2023Review
- Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease.Journal of hematopathology · 2023Article
- PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients.Annals of hematology · 2023Article
- [Chinese consensus on minimal residual disease detection and interpretation of patients with acute lymphoblastic leukemia (2023)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Adult patients with Ph+ ALL benefit from conditioning regimen of medium-dose VP16 plus CY/TBI.Hematological oncology · 2022Article
- Elucidating minimal residual disease of paediatric B-cell acute lymphoblastic leukaemia by single-cell analysis.Nature cell biology · 2022Article
- Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.Cancer discovery · 2021Review
- Pan-PI3Ki targets multiple B-ALL microenvironment interactions that fuel systemic and CNS relapse.Leukemia & lymphoma · 2021Article
- Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.Leukemia · 2021Review
- Systematic application of fluorescence in situ hybridization and immunophenotype profile for the identification of ZNF384 gene rearrangements in B cell acute lymphoblastic leukemia.International journal of laboratory hematology · 2021Article
- Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2020Review
- Evaluation and management of measurable residual disease in acute lymphoblastic leukemia.Therapeutic advances in hematology · 2020Review
- Re-Emergence of Minimal Residual Disease Detected by Flow Cytometry Predicts an Adverse Outcome in Pediatric Acute Lymphoblastic Leukemia.Frontiers in oncology · 2020Article
- The prognostic significance of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell lymphoblastic leukemia without minimal residual disease.Scientific reports · 2019Article
- Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia.Frontiers in immunology · 2019Review
- A Next-Generation Sequencing Primer-How Does It Work and What Can It Do?Academic pathologyReview
- Role of Autophagy and Apoptosis in Acute Lymphoblastic Leukemia.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the identification of minimal residual disease (MRD) that persists after chemotherapy has emerged as the most powerful tool in determining the prognosis of patients with ALL, often superseding historically relevant prognostic factors. Multiple methods to detect MRD exist, each with their own advantages and disadvantages. Multiparameter flow cytometry and quantitative polymerase chain reaction are the most commonly used methods of MRD detection in clinical practice, although there is promise in the use of more sensitive assays utilizing next-generation sequencing that may be able to further refine MRD-based risk stratification. By accurately identifying patients with persistent MRD who are at highest risk for relapse, we may be able to better design rational post-remission therapies using novel agents, such as inotuzumab ozogamicin, blinatumomab, and CD19-directed chimeric antigen receptor T cells, all of which have been shown to be effective in achieving MRD negativity, even in patients with relapsed or refractory disease. Future studies will be required to determine whether these post-remission strategies can obviate the need for allogeneic stem cell transplantation for patients with ALL in whom MRD can be eradicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.